ACM
BCTX

Altium Capital Management’s Briacell Therapeutics BCTX Stock Holding History

Altium Capital Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,335
Closed -$4.27M – 125
2021
Q2 		$4.27M Buy
+5,335
New +$3.33M 0.99% 34

Other funds holding BCTX

Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $87.6B AUM 131.08% 1-Year Est. Return

Altium Capital Management's BCTX Position: Q3 2021 in Review

Altium Capital Management sold out of Briacell Therapeutics (BCTX) in Q3 2021, closing a stake of 5,335 shares — an estimated $4.27M sold.

Altium Capital Management first reported a position in BCTX in Q2 2021 and held it in 1 quarter. The position peaked at $4.27M in Q2 2021. 19 funds tracked by Wall St. Rank hold BCTX as of Q3 2021.

  • Altium Capital Management reported no remaining Briacell Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Altium Capital Management sold 5,335 Briacell Therapeutics shares in Q3 2021, an estimated $4.27M.
  • Altium Capital Management first reported a position in Briacell Therapeutics in Q2 2021 and held it in 1 quarter.
  • Altium Capital Management's Briacell Therapeutics position peaked at $4.27M in Q2 2021.
  • 19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q3 2021.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.